The targeted inhibition of epidermal growth factor receptor (EGFR) has represented a milestone in the treatment of lung cancer. Several studies convincingly and consistently demonstrated a significant superiority of EGFR-TKIs over standard platinum-chemotherapy in EGFR-mutated NSCLC patients, leading to the sequential approval of gefitinib, erlotinib and afatinib as new standard first-line clinical treatment. To date we are witnessing a second revolution in the management of EGFR-positive NSCLC thanks to the development of new treatment strategies aiming to overcome acquired resistance to TKIs and ultimately improve patients’ outcomes. In this review we summarize the most important recent findings regarding EGFR-inhibition in NSCLC, highlighting the current unsolved questions on the selection of the best TKI in first-line, which therapy can be combined with upfront EGFR-TKIs, how to overcome acquired resistance, and which are the clinical applications of liquid biopsy.

Passiglia, F., Listì, A., Castiglia, M., Perez, A., Rizzo, S., Bazan, V., et al. (2017). EGFR inhibition in NSCLC: New findings…. and opened questions?. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 112, 126-135 [10.1016/j.critrevonc.2017.02.009].

EGFR inhibition in NSCLC: New findings…. and opened questions?

PASSIGLIA, Francesco;LISTI', Angela;CASTIGLIA, Marta;Perez, Alessandro;RIZZO, Sergio;BAZAN, Viviana;RUSSO, Antonio
2017

Abstract

The targeted inhibition of epidermal growth factor receptor (EGFR) has represented a milestone in the treatment of lung cancer. Several studies convincingly and consistently demonstrated a significant superiority of EGFR-TKIs over standard platinum-chemotherapy in EGFR-mutated NSCLC patients, leading to the sequential approval of gefitinib, erlotinib and afatinib as new standard first-line clinical treatment. To date we are witnessing a second revolution in the management of EGFR-positive NSCLC thanks to the development of new treatment strategies aiming to overcome acquired resistance to TKIs and ultimately improve patients’ outcomes. In this review we summarize the most important recent findings regarding EGFR-inhibition in NSCLC, highlighting the current unsolved questions on the selection of the best TKI in first-line, which therapy can be combined with upfront EGFR-TKIs, how to overcome acquired resistance, and which are the clinical applications of liquid biopsy.
www.elsevier.com/locate/critrevonc
Passiglia, F., Listì, A., Castiglia, M., Perez, A., Rizzo, S., Bazan, V., et al. (2017). EGFR inhibition in NSCLC: New findings…. and opened questions?. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 112, 126-135 [10.1016/j.critrevonc.2017.02.009].
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1040842817300288-main.pdf

accesso aperto

Dimensione 1.06 MB
Formato Adobe PDF
1.06 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10447/234299
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 19
social impact